News
Stopping the cycle: combination therapy reduces growth of androgen-receptor positive breast and prostate cancers
Treating androgen receptor (AR)-positive prostate and breast cancer with two drugs that block AR and cyclin-dependent kinase activity slows proliferation of cancer cells.
An optimized tool for the development of novel therapies for treatment-resistant prostate cancer
The development of novel therapeutics for the treatment of chemotherapy-resistant prostate cancer relies on disease models that accurately mimic the progression of human disease. When transferred into mice, a particular cell line does just that, allowing researchers to test the efficacy of potential drugs. But studies have shown that the cell line suffers from a lack of reproducibility and that an improved model of treatment-resistant prostate cancer is needed.
Cancer drug synergizes with radiation therapy in treatment-resistant prostate cancer
In a new study published in the journal Cancers, led by GSC Distinguished Scientist Dr. Marianne Sadar, researchers have demonstrated a potential synergistic treatment strategy for resistant cases of prostate cancer.
From fighting marine contaminants to fishing for cancer treatments from marine sponges: how a GSC biochemist made a drug discovery breakthrough
Dr. Marianne Sadar is not one to back down from a challenge. So even when told it wasn’t possible, she did something no one else dared to try.
Canada’s Michael Smith Genome Sciences Centre respectfully acknowledges that we operate on the traditional, ancestral and unceded territories of the xʷməθkwəy̓əm (Musqueam), Səl̓ílwətaʔ/Selilwitulh (Tsleil-Waututh), and Skwxwú7mesh (Squamish) nations who have cared and nurtured this land for all time. We give thanks, as uninvited guests, to be able to live and work on these lands.
